Fig 1.
Flow chart of study inclusion based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[27].
Fig 2.
Frequency of published economic evaluations on Crohn’s disease and ulcerative colitis over time; grey bars indicate year of market approval by the European Medicines Agency (EMA).
Table 1.
Key characteristics of published economic evaluations in Crohn’s disease and ulcerative colitis.
Table 2.
Summary of cost-effectiveness results adjusted to 2015 PPP for studies on Crohn’s disease.
Table 3.
Summary of cost-effectiveness results adjusted to 2015 PPP for studies on ulcerative colitis.